Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology company, for $1.6 billion. This move is part of Lilly’s strategic initiative to enhance its immuno-oncology program, one of the most promising areas in cancer research today. Details of the […]
Roche, the Swiss pharmaceutical giant, has announced its plans to fully acquire Flatiron Health, a leading oncology software company, for $1.9 billion. This strategic move aims to fast-track the development of cancer treatments by leveraging Flatiron Health’s advanced data analytics and electronic health records software. Strategic Expansion in Oncology The acquisition marks a significant step […]